Xiaflex Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The xiaflex market research report is one of a series of new reports that provides xiaflex market statistics, including xiaflex industry global market size, regional shares, competitors with a xiaflex market share, detailed xiaflex market segments, market trends and opportunities, and any further data you may need to thrive in the xiaflex industry. This xiaflex market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The growth in the forecast period can be attributed to Increasing adoption of minimally invasive treatments, growing awareness of Xiaflex treatment options, growing aging population. Major trends in the forecast period include Advancements in injection techniques, innovations in delivery systems, expansion of indications for Peyronie’s disease and Dupuytren’s contracture, advancements in injection techniques, innovations in delivery systems.

The increasing prevalence of Peyronie’s disease is expected to drive the growth of the Xiaflex market. Peyronie’s disease is a connective tissue disorder that leads to the formation of fibrous plaques in the penis, resulting in curvature and discomfort. Factors such as aging, genetics, and tissue damage from injury contribute to the rise in Peyronie’s disease cases. Xiaflex works by breaking down these fibrous plaques, improving penile curvature and function. According to data published by The Urology Care Foundation in February 2023, approximately 4 out of every 100 men aged 40 to 70 experience Peyronie’s disease, and about 0.5% of adult men in the U.S. are diagnosed with this condition. As the prevalence of Peyronie’s disease continues to grow, it is expected to drive increased demand for Xiaflex.

A key trend in the Xiaflex market involves exploring alternative treatment protocols for cases that are resistant to conventional therapies. There is growing interest in investigating the use of Xiaflex in surgical applications, aiming to reduce the need for invasive procedures and improve recovery times. In May 2024, Endo International Plc, a U.S.-based pharmaceutical company, presented new data at the American Urological Association’s annual meeting, focusing on the efficacy of Xiaflex for treating Peyronie’s disease. This research compared Xiaflex with surgical approaches and investigated new treatment protocols for patients who did not respond to prior therapies. These ongoing studies underscore Endo’s commitment to enhancing Xiaflex’s clinical outcomes and expanding its potential uses in treating a variety of conditions.

In April 2024, Endo Inc., a U.S.-based specialty pharmaceutical company, completed the acquisition of assets from Endo International plc for an undisclosed amount. This acquisition resulted in the creation of a new entity with a diversified product portfolio, positioning Endo for long-term growth and strategic development. Endo International plc, known for its work in both generic and branded drug manufacturing, is the company behind the development of Xiaflex.

The key company operating in the xiaflex market is Endo Inc.

North America was the largest region in the xiaflex market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in xiaflex report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the xiaflex market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Xiaflex (collagenase clostridium histolyticum) is a biologic injectable treatment used to manage Dupuytren's contracture and Peyronie's disease. It works by enzymatically breaking down the collagen responsible for tissue buildup, which causes the contracture of affected tendons or plaques. Administered via subcutaneous injection by a healthcare professional, Xiaflex is typically used for patients who are not candidates for surgery or those seeking an alternative treatment.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The primary indications for xiaflex include Dupuytren’s contracture, Peyronie’s disease, and other conditions. Dupuytren’s contracture is a condition where tissue beneath the skin of the palm thickens, forming nodules that cause the fingers to bend inward. xiaflex helps by breaking down the collagen buildup, thereby improving finger mobility and hand function. Distribution channels for Xiaflex include hospital pharmacies, retail pharmacies, and online pharmacies, and it is primarily used by adults and geriatric patients.

The xiaflex market consists of sales of single-use vials containing collagenase clostridium histolyticum for injectable use. Values in this market are ‘factory gate’ values, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.